Gene,Alterations,Cancer_types,Drugs,Level,Variation,Proportion
ABL1,T315I,B-Lymphoblastic Leukemia/Lymphoma,Ponatinib,Level 1,Mutation,0.056
ABL1,T315I,Chronic Myelogenous Leukemia,Asciminib,Level 1,Mutation,0.056
ABL1,T315I,Chronic Myelogenous Leukemia,Ponatinib,Level 1,Mutation,0.056
ATM,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Olaparib,Level 1,Mutation,0.056
BARD1,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Olaparib,Level 1,Mutation,0.167
BRAF,V600,Erdheim-Chester Disease,Vemurafenib,Level 1,Mutation,0.111
BRAF,V600,Melanoma,Vemurafenib + Atezolizumab + Cobimetinib,Level 1,Mutation,0.111
BRAF,V600E,Anaplastic Thyroid Cancer,Dabrafenib + Trametinib,Level 1,Mutation,0.111
BRAF,V600E,Colorectal Cancer,Encorafenib + Cetuximab,Level 1,Mutation,0.111
BRAF,V600E,Melanoma,Dabrafenib,Level 1,Mutation,0.111
BRAF,V600E,Melanoma,Vemurafenib,Level 1,Mutation,0.111
BRAF,V600E,Non-Small Cell Lung Cancer,Dabrafenib + Trametinib,Level 1,Mutation,0.111
BRAF,"V600E, V600K",Melanoma,Dabrafenib + Trametinib,Level 1,Mutation,0.111
BRAF,"V600E, V600K",Melanoma,Encorafenib + Binimetinib,Level 1,Mutation,0.111
BRAF,"V600E, V600K",Melanoma,Trametinib,Level 1,Mutation,0.111
BRAF,"V600E, V600K",Melanoma,Vemurafenib + Cobimetinib,Level 1,Mutation,0.111
BRCA1,Oncogenic Mutations,"Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma",Niraparib,Level 1,Mutation,0.111
BRCA1,Oncogenic Mutations,"Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma","Olaparib, Olaparib + Bevacizumab",Level 1,Mutation,0.111
BRCA1,Oncogenic Mutations,"Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma",Rucaparib,Level 1,Mutation,0.111
BRCA1,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Olaparib,Level 1,Mutation,0.111
BRCA1,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Rucaparib,Level 1,Mutation,0.111
BRCA2,Oncogenic Mutations,"Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma",Niraparib,Level 1,Mutation,0.167
BRCA2,Oncogenic Mutations,"Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma","Olaparib, Olaparib + Bevacizumab",Level 1,Mutation,0.167
BRCA2,Oncogenic Mutations,"Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma",Rucaparib,Level 1,Mutation,0.167
BRCA2,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Olaparib,Level 1,Mutation,0.167
BRCA2,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Rucaparib,Level 1,Mutation,0.167
BRIP1,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Olaparib,Level 1,Mutation,0.056
CDK12,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Olaparib,Level 1,Mutation,0.056
EGFR,"Exon 19 in-frame deletions, L858R",Non-Small Cell Lung Cancer,Afatinib,Level 1,Mutation,0.056
EGFR,"Exon 19 in-frame deletions, L858R",Non-Small Cell Lung Cancer,Dacomitinib,Level 1,Mutation,0.056
EGFR,"Exon 19 in-frame deletions, L858R",Non-Small Cell Lung Cancer,"Erlotinib, Erlotinib + Ramucirumab",Level 1,Mutation,0.056
EGFR,"Exon 19 in-frame deletions, L858R",Non-Small Cell Lung Cancer,Gefitinib,Level 1,Mutation,0.056
EGFR,"Exon 19 in-frame deletions, L858R",Non-Small Cell Lung Cancer,Osimertinib,Level 1,Mutation,0.056
EGFR,Exon 20 in-frame insertions,Non-Small Cell Lung Cancer,Amivantamab,Level 1,Mutation,0.056
EGFR,Exon 20 in-frame insertions,Non-Small Cell Lung Cancer,Mobocertinib,Level 1,Mutation,0.056
EGFR,G719,Non-Small Cell Lung Cancer,Afatinib,Level 1,Mutation,0.056
EGFR,L861Q,Non-Small Cell Lung Cancer,Afatinib,Level 1,Mutation,0.056
EGFR,S768I,Non-Small Cell Lung Cancer,Afatinib,Level 1,Mutation,0.056
EGFR,T790M,Non-Small Cell Lung Cancer,Osimertinib,Level 1,Mutation,0.056
MET,"D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations",Non-Small Cell Lung Cancer,Capmatinib,Level 1,Mutation,0.056
MET,"D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations",Non-Small Cell Lung Cancer,Tepotinib,Level 1,Mutation,0.056
PDGFRA,"Exon 18 in-frame deletions, Exon 18 in-frame insertions, Exon 18 missense mutations",Gastrointestinal Stromal Tumor,Avapritinib,Level 1,Mutation,0.111
PIK3CA,C420R and 10 other alterations,Breast Cancer,Alpelisib + Fulvestrant,Level 1,Mutation,0.056
RAD51D,Oncogenic Mutations,"Prostate Cancer, NOS, Prostate Cancer",Olaparib,Level 1,Mutation,0.056
ABL1,E255K and 9 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Bosutinib,Level 2,Mutation,0.056
ABL1,E255K and 9 other alterations,Chronic Myelogenous Leukemia,Bosutinib,Level 2,Mutation,0.056
ABL1,E255K and 5 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Dasatinib,Level 2,Mutation,0.056
ABL1,E255K and 5 other alterations,Chronic Myelogenous Leukemia,Dasatinib,Level 2,Mutation,0.056
ABL1,F317C and 5 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Nilotinib,Level 2,Mutation,0.056
ABL1,F317C and 5 other alterations,Chronic Myelogenous Leukemia,Nilotinib,Level 2,Mutation,0.056
BRAF,Oncogenic Mutations (excluding V600),Erdheim-Chester Disease,"Cobimetinib, Trametinib",Level 2,Mutation,0.111
BRAF,Oncogenic Mutations (excluding V600),Langerhans Cell Histiocytosis,"Cobimetinib, Trametinib",Level 2,Mutation,0.111
BRAF,Oncogenic Mutations (excluding V600),Rosai-Dorfman Disease,"Cobimetinib, Trametinib",Level 2,Mutation,0.111
BRAF,V600,Langerhans Cell Histiocytosis,"Vemurafenib, Dabrafenib",Level 2,Mutation,0.111
BRAF,V600 (excluding V600E and V600K),Melanoma,Dabrafenib + Trametinib,Level 2,Mutation,0.111
BRAF,V600 (excluding V600E and V600K),Melanoma,Encorafenib + Binimetinib,Level 2,Mutation,0.111
BRAF,V600 (excluding V600E and V600K),Melanoma,Vemurafenib + Cobimetinib,Level 2,Mutation,0.111
BRAF,V600E,"Biliary Tract Cancer, NOS",Dabrafenib + Trametinib,Level 2,Mutation,0.111
BRAF,V600E,Colorectal Cancer,Encorafenib + Panitumumab,Level 2,Mutation,0.111
BRAF,V600E,Diffuse Glioma,"Dabrafenib + Trametinib, Vemurafenib + Cobimetinib",Level 2,Mutation,0.111
BRAF,V600E,Encapsulated Glioma,"Dabrafenib + Trametinib, Vemurafenib + Cobimetinib",Level 2,Mutation,0.111
BRAF,V600E,"Ganglioglioma, Pleomorphic Xanthoastrocytoma, Pilocytic Astrocytoma","Dabrafenib + Trametinib, Vemurafenib + Cobimetinib",Level 2,Mutation,0.111
BRAF,V600E,Hairy Cell Leukemia,Vemurafenib,Level 2,Mutation,0.111
BRAF,V600E,Pilocytic Astrocytoma,Selumetinib,Level 2,Mutation,0.111
BRCA1,Oncogenic Mutations,"Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas",Rucaparib,Level 2,Mutation,0.111
BRCA2,Oncogenic Mutations,"Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas",Rucaparib,Level 2,Mutation,0.167
BRCA2,Oncogenic Mutations,Uterine Sarcoma,"Olaparib, Rucaparib, Niraparib",Level 2,Mutation,0.167
EGFR,A763_Y764insFQEA,Non-Small Cell Lung Cancer,Erlotinib,Level 2,Mutation,0.056
EGFR,G719,Non-Small Cell Lung Cancer,Osimertinib,Level 2,Mutation,0.056
EGFR,L861Q,Non-Small Cell Lung Cancer,Osimertinib,Level 2,Mutation,0.056
EGFR,S768I,Non-Small Cell Lung Cancer,Osimertinib,Level 2,Mutation,0.056
MET,"D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations",Non-Small Cell Lung Cancer,Crizotinib,Level 2,Mutation,0.056
PDGFRA,D842V,Gastrointestinal Stromal Tumor,Dasatinib,Level 2,Mutation,0.111
PDGFRA,Oncogenic Mutations,Gastrointestinal Stromal Tumor,Imatinib,Level 2,Mutation,0.111
PDGFRA,Oncogenic Mutations,Gastrointestinal Stromal Tumor,Regorafenib,Level 2,Mutation,0.111
PDGFRA,Oncogenic Mutations,Gastrointestinal Stromal Tumor,Ripretinib,Level 2,Mutation,0.111
PDGFRA,Oncogenic Mutations,Gastrointestinal Stromal Tumor,Sunitinib,Level 2,Mutation,0.111
PIK3CA,"Oncogenic Mutations (excluding C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R and H1047Y)",Breast Cancer,Alpelisib + Fulvestrant,Level 2,Mutation,0.056
BRAF,K601,Melanoma,Trametinib,Level 3,Mutation,0.111
BRAF,L597,Melanoma,Trametinib,Level 3,Mutation,0.111
BRAF,Oncogenic Mutations (excluding V600),Histiocytosis,"Cobimetinib, Trametinib",Level 3,Mutation,0.111
BRAF,V600,Histiocytosis,"Vemurafenib, Dabrafenib",Level 3,Mutation,0.111
BRCA1,Oncogenic Mutations,Breast Cancer,Olaparib,Level 3,Mutation,0.111
BRCA1,Oncogenic Mutations,Breast Cancer,Talazoparib,Level 3,Mutation,0.111
BRCA1,Oncogenic Mutations,"Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas",Olaparib,Level 3,Mutation,0.111
BRCA2,Oncogenic Mutations,Breast Cancer,Olaparib,Level 3,Mutation,0.167
BRCA2,Oncogenic Mutations,Breast Cancer,Talazoparib,Level 3,Mutation,0.167
BRCA2,Oncogenic Mutations,"Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas",Olaparib,Level 3,Mutation,0.167
EGFR,E709_T710delinsD,Non-Small Cell Lung Cancer,Afatinib,Level 3,Mutation,0.056
EGFR,Exon 19 in-frame deletions?and?5?other alterations,Non-Small Cell Lung Cancer,Patritumab Deruxtecan,Level 3,Mutation,0.056
EGFR,Exon 19 in-frame insertions,Non-Small Cell Lung Cancer,Erlotinib,Level 3,Mutation,0.056
EGFR,Exon 19 in-frame insertions,Non-Small Cell Lung Cancer,Gefitinib,Level 3,Mutation,0.056
EGFR,Exon 20 in-frame insertions,Non-Small Cell Lung Cancer,CLN-081,Level 3,Mutation,0.056
EGFR,Exon 20 in-frame insertions,Non-Small Cell Lung Cancer,Poziotinib,Level 3,Mutation,0.056
ESR1,Oncogenic Mutations,Breast Cancer,"AZD9496, Fulvestrant",Level 3,Mutation,0.111
MET,Y1003,Non-Small Cell Lung Cancer,"Tepotinib, Capmatinib, Crizotinib",Level 3,Mutation,0.056
PTCH1,Truncating Mutations,Medulloblastoma,"Sonidegib, Vismodegib",Level 3,Mutation,0.056
ARID1A,Truncating Mutations,All Solid Tumors,PLX2853,Level 4,Mutation,0.056
ARID1A,Truncating Mutations,All Solid Tumors,Tazemetostat,Level 4,Mutation,0.056
BRAF,"G464,?G469A,?G469R,?G469V",All Solid Tumors,PLX8394,Level 4,Mutation,0.111
BRAF,K601,All Solid Tumors,PLX8394,Level 4,Mutation,0.111
BRAF,L597,All Solid Tumors,PLX8394,Level 4,Mutation,0.111
CDK12,Truncating Mutations,All Solid Tumors,"Pembrolizumab, Nivolumab, Cemiplimab",Level 4,Mutation,0.056
EGFR,"A289V,?R108K,?T263P",Glioma,Lapatinib,Level 4,Mutation,0.056
EGFR,A763_Y764insFQEA,Non-Small Cell Lung Cancer,Afatinib,Level 4,Mutation,0.056
EGFR,D761Y,Non-Small Cell Lung Cancer,Osimertinib,Level 4,Mutation,0.056
EGFR,Exon 19 in-frame insertions,Non-Small Cell Lung Cancer,Afatinib,Level 4,Mutation,0.056
EGFR,L718V,Non-Small Cell Lung Cancer,Afatinib,Level 4,Mutation,0.056
EGFR,L747P,Non-Small Cell Lung Cancer,Afatinib,Level 4,Mutation,0.056
KDM6A,Oncogenic Mutations,Bladder Cancer,Tazemetostat,Level 4,Mutation,0.056
PTEN,Oncogenic Mutations,All Solid Tumors,"GSK2636771, AZD8186",Level 4,Mutation,0.056
ERBB2,Amplification,Breast Cancer,Ado-Trastuzumab Emtansine,Level 1,Amplification,0.056
ERBB2,Amplification,Breast Cancer,"Lapatinib + Capecitabine, Lapatinib + Letrozole",Level 1,Amplification,0.056
ERBB2,Amplification,Breast Cancer,Margetuximab + Chemotherapy,Level 1,Amplification,0.056
ERBB2,Amplification,Breast Cancer,"Neratinib, Neratinib + Capecitabine",Level 1,Amplification,0.056
ERBB2,Amplification,Breast Cancer,Trastuzumab + Pertuzumab + Chemotherapy,Level 1,Amplification,0.056
ERBB2,Amplification,Breast Cancer,Trastuzumab + Tucatinib + Capecitabine,Level 1,Amplification,0.056
ERBB2,Amplification,Breast Cancer,Trastuzumab Deruxtecan,Level 1,Amplification,0.056
ERBB2,Amplification,Breast Cancer,"Trastuzumab, Trastuzumab + Chemotherapy",Level 1,Amplification,0.056
ERBB2,Amplification,Esophagogastric Cancer,Pembrolizumab + Trastuzumab + Chemotherapy,Level 1,Amplification,0.056
ERBB2,Amplification,Esophagogastric Cancer,Trastuzumab + Chemotherapy,Level 1,Amplification,0.056
ERBB2,Amplification,Esophagogastric Cancer,Trastuzumab Deruxtecan,Level 1,Amplification,0.056
ERBB2,Amplification,Colorectal Cancer,Lapatinib + Trastuzumab,Level 2,Amplification,0.056
ERBB2,Amplification,Colorectal Cancer,Trastuzumab + Pertuzumab,Level 2,Amplification,0.056
ERBB2,Amplification,Colorectal Cancer,Trastuzumab Deruxtecan,Level 2,Amplification,0.056
ERBB2,Amplification,Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma,Trastuzumab + Carboplatin-Taxol Regimen,Level 2,Amplification,0.056
MET,Amplification,Non-Small Cell Lung Cancer,Capmatinib,Level 2,Amplification,0.111
MET,Amplification,Non-Small Cell Lung Cancer,Crizotinib,Level 2,Amplification,0.111
MET,Amplification,Non-Small Cell Lung Cancer,Tepotinib,Level 2,Amplification,0.111
FGFR1,Amplification,Lung Squamous Cell Carcinoma,"Debio1347, Infigratinib, Erdafitinib",Level 3,Amplification,0.222
CDK4,Amplification,"Dedifferentiated Liposarcoma, Well-Differentiated Liposarcoma","Palbociclib, Abemaciclib",Level 4,Amplification,0.056
EGFR,Amplification,Glioma,Lapatinib,Level 4,Amplification,0.056
SMARCB1,Deletion,Epithelioid Sarcoma,Tazemetostat,Level 1,Deletion,0.056